



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Anti-Gn [Mab-2 (23B5-1)] Bulk Size Ab03816-10.3-BT

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

Isotype and Format: Human IgG1, Fc Silent™, Kappa

Clone Number: Mab-2 (23B5-1)

Alternative Name(s) of Target: RVFV Gn; p78; Glycoprotein G1; Glycoprotein N

UniProt Accession Number of Target Protein: P21401

Published Application(s): in vivo, neutralization, ELISA

Published Species Reactivity: Rift Valley fever virus

Immunogen: The original antibody was generated by immunizing mice with bacterially produced RVFV Gn protein.

Specificity: The antibody is specific for the Gn protein binding an epitope in the β 1 structural domain (aa 301 to 365). Gn is a surface glycoprotein of RVFV.

Application Notes: The specificity of the original format of the antibody to Gn from RVFV lysate was confirmed by ELISA analysis (EC = 8.8 ng/mL). The antibody was neutralizing, with an IC50 of 1.5 ng/ml. To determine the protective potential of the IgG1 antibody, it was administered to C57BL/6 mice in a RVFV lethal challenge model. IgG1 isotype control-treated mice succumbed to disease within 3 days of challenge, while the antibody protected mice, with only one mouse succumbing to disease. The IgG2a version of the antibody was constructed. It exhibited an RVFV neutralization capacity and ELISA affinity similar to that of its IgG1 counterpart. Further, the IgG2a version showed significantly higher NK cell degranulation. In vivo experiments demonstrated that the IgG2a format of the antibody fully protected mice from lethal challenge (Cartwright et al., 2021; PMID:34494884).

Antibody First Published in: Cartwright et al. Isotype-specific Fc effector functions enhance antibody-mediated Rift Valley Fever virus protection in vivo. mSphere. 2021 Oct 27;6(5):e0055621. [PMID:34494884](#)

Note on publication: The original paper describes the generation and characterization of the antibody.

Product Form

Size:

1 mg Purified antibody in bulk size.

Purification: Protein A affinity purified

Supplied In: PBS only.

Storage Recommendation: Store at 4°C for up to 3 months. Note, this antibody is provided without added preservatives, it is therefore recommended this antibody be handled under sterile conditions. For longer storage, aliquot and store at -20°C.

Concentration: 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.